Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00

Sensei Biotherapeutics (NASDAQ:SNSE) had its price target raised by research analysts at Oppenheimer from $3.50 to $4.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Sensei Biotherapeutics in a research report on Friday.

Sensei Biotherapeutics Stock Up 17.2 %

Shares of SNSE stock opened at $0.51 on Friday. The firm has a market cap of $12.70 million, a price-to-earnings ratio of -0.42 and a beta of 0.16. Sensei Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.94. The company’s 50 day moving average is $0.47 and its 200 day moving average is $0.49.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd lifted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,903 shares of the company’s stock after purchasing an additional 48,977 shares during the quarter. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.